Compare AstraZeneca plc (AZN) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs VanEck Vietnam ETF — how do they compare? AstraZeneca plc trades at $158.61 (market cap $248.14B), while VanEck Vietnam ETF trades at $17.84. The key difference: AstraZeneca plc pays a 2.01% dividend while VanEck Vietnam ETF pays none, and VanEck Vietnam ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | VNM | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $19.80 |
52-Week Low | $147.06 | $16.34 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
VNM trades at $17.83, up 1.08% today, with a bullish overall technical signal from indicators. The stock shows mixed technical signals with bearish moving averages but bullish ADX readings, while support and resistance cluster tightly around $17-$18. Recent news highlights Vietnam's economic challenges, including power grid strain and foreign capital outflows from Asian equities, potentially impacting the ETF's holdings.
The outlook is cautious due to Vietnam's macroeconomic headwinds and ETF underperformance, though potential exists from FTSE Russell's EM reclassification. Key risks include regional economic volatility and sector-specific pressures, while institutional sentiment remains watchful amid these developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
